## NURSING CLINICAL STANDARD

## **INOTROPE INFUSION - ICU**

**PURPOSE:** 

To outline the management of the patient receiving inotropic infusion.

SUPPORTIVE DATA:

Inotropes are drugs that enhance cardiac contractility. Increased contractility results in improved cardiac output and perfusion. Dobutamine and milrinone are the commonly used inotropes. Inotropes may increase myocardial workload and oxygen demand. These agents may be ineffective if intravascular fluid status is inadequate or acid-base abnormalities are uncorrected. At high doses, excessive myocardial stimulation can occur, leading to tachycardia and tachydysrhythmias. Unlike vasopressors, inotropes cannot be titrated by the nurse at the bedside. A new provider order is required for each dose change.

See Vasopressor Standard for management of dopamine infusions.

ASSESSMENT:

- 1. Assess the following prior to administration:
  - Vital signs
  - Hemodynamic parameters from pulmonary artery catheter if present (e.g. Cardiac Output, RA, PAWP, SVR)
  - CVP from central line (if present and ordered)
  - Arterial blood gases/ Venous blood gases (as ordered)
  - Electrocardiogram (ECG) rhythm
  - Level of consciousness (LOC)
  - Urine output
- 2. Determine concentration and verify dosage upon initiation, within one hour of assuming care of the patient or earlier as clinically appropriate, and with bag changes. In addition, verify accurate dosage with every rate change order.
- 3. Assess the following a minimum of every hour
  - Vital Signs
    - For tachycardia
    - For hypertension
    - For hypotension
      - Adults: MAP less than 60 or as defined by the provider
      - Peds: as defined by the provider
      - > DO NOT administer loading dose milrinone if patient is hypotensive
  - ECG rhythm
  - For extravasation if infused via a peripheral line
- 4. Assess vital signs and hemodynamic parameters (as applicable) 5-10 minutes post-rate change until desired parameters are achieved, then per Unit Structure Standards.
- 5. Assess for adverse reactions/side effects a minimum of every 4 hours:
  - Altered LOC
  - Chest pain
  - Diminished peripheral pulses
  - Cardiac arrhythmias
- 6. Monitor as ordered:
  - Platelet levels, liver function tests (milrinone)
  - Blood gases

ADMINISTRATION:

- 7. Administer inotrope as ordered. Order to include:
  - Dose/rate
  - Titration parameters should not be included in the order. A new provider order is required for each dose change

SAFETY:

8. Administer inotrope infusion via infusion pump with Guardrails. Use a central line

whenever possible. If using a peripheral line, check for extravasation hourly.

9. Infuse medications as ordered

(NICU refer to Neofax; PICU -refer to the Pediatric Drug Dosage Handbook and Formulary). See table for recommended adult doses.

\*Note if Dose exceeds recommended max; notation that "Name of Attending is aware" should be in comments section of medication order.

- 10. Ensure the following:
  - Patent IV access
- DISCONTINUATION:
- Infusion pump with Guardrails is used for administration
- Drug concentration and dosages are correct and within ordered parameters
- Drug compatibility
- REPORTABLE CONDITIONS:
- 11. Discontinue infusion as ordered.
  - Each reduction in dose requires a new provider order
- 12. Notify the provider for:
  - Signs of adverse reactions
- PATIENT/CAREGIVER EDUCATION:
- Inability to achieve desired effects within infusion limits
- Extravasation
- Significant change in vital signs
- 13. Instruct on the following:
- ADDITIONAL STANDARDS:

- Purpose of inotrope
- Need for frequent monitoring
- Notification of RN for complaints of chest pain
- 14. Implement the following as indicated:
  - Arterial Line ICU
  - Oxygen Therapy
  - Pulmonary Artery Catheter ICU
  - Central line
  - IV therapy
- REFERENCES:

DOCUMENTATION:

15. Document in accordance with documentation standards.

LAC+USC Clinical Resources: Micromedix and UptoDate drug info (Lexi-comp) Consult: LAC+USC Department of Pharmacy

## ADULT DOSAGES (Administer per provider's order)

MEDICATION INITIAL DOCE LIGHAL DOCE LIGHAL				
MEDICATION	INITIAL DOSE	USUAL DOSE	USUAL	
			TITRATION	
			RATE:	
			*EACH DOSE	
			CHANGE	
			REQUIRES	
			NEW	
			PROVIDER	
			ORDER	
Dobutamine	2.5-5 mcg/kg/minute	2.5-10 mcg/kg/minute	*2-3	
			mcg/kg/minute	
		Maximum:20*mcg/kg/minute	every 10-30	
		Wiaximum.20 meg/kg/mmute	minutes	
		43.5	minucs	
		*May be exceeded, with		
		attending physician approval,		
		up to max 40 mcg/kg/min		
Milrinone	50 mcg/kg over 10 minutes	0.375-0.75 mcg/kg/minute	*0.25-0.5	
1.11111110110	30 meg/kg over 10 minutes		mcg/kg/minute	
	D: 0.255 // / ·	(Decrease dose in renal		
	Drip: 0.375 mcg/kg/minute	dysfunction- consult with	every 5-15	
		pharmacist)	minutes	
		1		

Initial date approved: 02/95	Reviewed and approved by: Critical Care Committee Professional Practice Committee Pharmacy & Therapeutics Committee Nurse Executive Committee Attending Staff Association Executive Committee	Revision Date: 8/96, 11/00, 3/06, 8/09, 7/10, 11/14, 11/15, 12/20
------------------------------	---	---